Thursday 18 June 2026

The Pharma Letter Podcast — Episode 19 — US midterms and beyond: outlook for pharma

Pharmaceutical
Simon Wentworth
28 November 2022
us-midterms-and-beyond-1

More on this story...

Pharmaceutical
The Pharma Letter Podcast — Episode 17 — Inflation Reduction Act: quick take
17 August 2022
Pharmaceutical
Biden-Harris Administration moves on affordable and accessible healthcare
27 October 2022
Pharmaceutical
Biden names Renee Wegrzyn as first head of ARPA-H
13 September 2022




More ones to watch >




Today's issue

Two bills moving through US Senate HELP Committee welcomed by AAM
Biosimilars
Two bills moving through US Senate HELP Committee welcomed by AAM
18 June 2026
Pharmaceutical
F2G and Shionogi set up regulatory push for olorofim after Phase III win
18 June 2026
Pharmaceutical
FDA approves first oral carbapenem therapy for cUTIs
17 June 2026
Pharmaceutical
PwC: Biopharma dealmaking rebounds as pharma races to fill pipeline gaps
17 June 2026
Biotechnology
Jazz Pharmaceuticals strikes research deal with AbCellera
17 June 2026
Biotechnology
Nuclidium bets on copper as radiopharma moves beyond alpha-versus-beta debate
17 June 2026
Pharmaceutical
Over 90% reduced death risk with treatment in subgroup for ultra rare TK2d disease
17 June 2026


Company Spotlight

AbCellera
A Vancouver-based antibody discovery company that deploys high-throughput single-cell screening technology to identify and develop therapeutic antibodies across infectious disease, rare disease, and neurology.


More Features in Pharmaceutical

F2G and Shionogi set up regulatory push for olorofim after Phase III win
18 June 2026
FDA approves first oral carbapenem therapy for cUTIs
17 June 2026
PwC: Biopharma dealmaking rebounds as pharma races to fill pipeline gaps
17 June 2026
Over 90% reduced death risk with treatment in subgroup for ultra rare TK2d disease
17 June 2026


Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze